Should You Continue Tamplus Even If PSA Is Already Normal?
Yes, you should continue Tamplus (tamsulosin + finasteride combination) even if your PSA is normal, because the medication is treating your lower urinary tract symptoms and preventing disease progression—not just lowering PSA. PSA normalization is an expected pharmacological effect of finasteride, not an indication that treatment can be stopped.
Why PSA Normalization Doesn't Mean You Can Stop
Finasteride reduces PSA by approximately 40-50% within 6-12 months of treatment 1. This is a direct drug effect on the prostate gland, not a sign that your underlying benign prostatic hyperplasia (BPH) has resolved. The PSA reduction occurs because finasteride blocks the conversion of testosterone to dihydrotestosterone (DHT), which shrinks prostate tissue and reduces PSA production 2.
Key Evidence on PSA Changes with Finasteride:
- After 12 months of finasteride treatment, median PSA decreases by approximately 50% (range: 81% decrease to 20% increase) 3
- This reduction continues beyond the first year, with median decreases of 42-57% at 48 months 4
- The PSA reduction is highly variable between individuals—only 35% of men show the expected 40-60% decrease, while 30% have greater than 60% decrease 1
The Real Indications for Continuing Treatment
The appropriate indication for 5α-reductase inhibitors like finasteride is treating lower urinary tract symptoms (LUTS) in men with prostatic enlargement 2, 5, 6. The medication should be continued based on:
- Presence of bothersome LUTS (storage or voiding symptoms)
- Evidence of prostatic enlargement (prostate volume >30cc, PSA >1.5 ng/mL at baseline, or palpable enlargement) 7
- Prevention of disease progression (acute urinary retention, need for surgery)
Long-Term Benefits of Combination Therapy:
The CombAT trial demonstrated that combination therapy with dutasteride (similar to finasteride) plus tamsulosin significantly reduces the risk of:
These benefits persist over 4 years of treatment and are greatest in men with baseline prostate volume ≥40 mL or PSA ≥1.5 ng/mL 9.
When to Consider Stopping Treatment
You should only consider discontinuing Tamplus if:
- Your LUTS have completely resolved and cause no bother (though symptoms often return after stopping)
- You never had prostatic enlargement to begin with (prostate volume <30cc and PSA <1.5 ng/mL at baseline) 2
- You're experiencing intolerable side effects (sexual dysfunction, orthostatic hypotension)
Important Caveat About Stopping:
If you discontinue treatment after several days or weeks, you must restart at the lower tamsulosin dose (0.4 mg) rather than resuming at 0.8 mg if you were taking the higher dose 10. Additionally, stopping finasteride will result in PSA levels returning to baseline over 6-12 months, and prostate volume will gradually increase again.
Monitoring While on Treatment
Continue PSA monitoring even while on finasteride, because:
- Failure to achieve expected PSA decrease may indicate heightened prostate cancer risk 1
- Rising PSA while on finasteride warrants investigation 4
- The "doubling rule" (multiply measured PSA by 2) is unreliable for cancer screening in men on finasteride 1, 11
Practical Monitoring Approach:
- Measure PSA at baseline, 6 months, and 12 months after starting finasteride
- After 12 months, establish a new baseline and monitor for increases from this nadir
- Any sustained PSA rise from the on-treatment nadir should prompt urological evaluation 12
Bottom Line Algorithm
Continue Tamplus if:
- You have ongoing LUTS (even if mild)
- Your baseline prostate was enlarged (volume >30cc or PSA >1.5 ng/mL)
- You're tolerating the medication without significant side effects
- Your goal is to prevent future acute urinary retention or surgery
Consider stopping only if:
- You never had prostatic enlargement (volume <30cc AND baseline PSA <1.5 ng/mL)
- Your symptoms have completely resolved AND you accept the risk of symptom recurrence and disease progression
- You're experiencing intolerable adverse effects that outweigh benefits
The normalization of PSA is an expected drug effect, not a treatment endpoint. The decision to continue should be based on symptom control, prevention of progression, and tolerability—not PSA levels alone.